ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
ResMed (NYSE:RMD) reported Q2 CY2026 revenue of $1.46 billion, up 8.6% year on year and in line with Wall Street estimates. Non-GAAP EPS was $2.95, up from $2.55 a year earlier, about 2% above consensus. Analysts expect revenue to rise about 5% over the next 12 months and full-year EPS to grow from $11.17 to $12.15. Shares fell 5.9% to $208.65 after results.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results were in line on revenue and slightly above on adjusted EPS, but the stock dropped 5.9% immediately after, consistent with investor concern about forward growth deceleration and/or near-term margin pressure.
Market read
Traders can reassess near-term expectations given the reported in-line revenue, EPS beat, and the stated 12-month revenue growth outlook of 5% (deceleration).
What to watch
The text notes adjusted operating margin declined this quarter, which could be the real driver of the negative reaction, but it does not quantify the quarter’s margin level or provide detailed guidance.
Background
ResMed is a cloud-connected medical device and software company focused on sleep apnea and other respiratory disorders.
Ticker impact
ResMed reported Q2 CY2026 sales of $1.46B (+8.6% YoY) and adjusted EPS $2.95, beating consensus by 2%, yet shares fell 5.9% to $208.65.
Near-term downside risk persists while the market digests the implied deceleration in revenue growth expectations and any margin commentary not captured here.
The article provides the key print (sales, EPS, beat) and the immediate reaction (down 5.9%), plus a forward revenue growth expectation of 5% over 12 months, suggesting the market focused on deceleration rather than the beat.
Market effects
Signals that healthcare medtech investors may be prioritizing growth acceleration and forward trajectory over modest EPS beats.
No specific regional impact described beyond US-listed trading reaction.
No explicit global macro or international regulatory driver cited; constant-currency discussion suggests FX was not the driver.
Counterpoint
The selloff may be overdone if the core demand picture is intact, since constant-currency growth aligns with reported growth and EPS improved meaningfully YoY.
Key entities
- companyResMed
Reported Q2 CY2026 sales of $1.46B (+8.6% YoY) and adjusted EPS of $2.95 (+15.9% CAGR over five years), with shares down 5.9% after the release.
